Sartorius plans to integrate Respironics' proprietary sensor technology into its disposable bioreactors in an effort to become the "first company worldwide to offer bioreactors enabling required off-gas analysis using disposable technologies during the fermentation/bio-reaction process." This is a critical parameter for cell culturing in the fermenter or bioreactor to obtain active medical ingredients. Together with measurements of the substances added to the cell lines and of the parameters in the bioreactor, such as temperature or pH, off-gas analysis delivers overall information on cell activity and process stability of fermentation. Until now, this analysis had been carried out with equipment that had to be sterilized after every sampling procedure and that additionally entailed a high capital outlay of up to $25,000.
Respironics, an industry leader in carbon dioxide sensor technology, has historically offered, and continues to offer, its CAPNOSTAT 5 mainstream and LoFlo CAPNOSTAT 5 sidestream carbon dioxide sensor and carbon dioxide monitoring technology for use during recovery, in the intensive care unit, in emergency medicine/transport, and for respiratory care. The CAPNOSTAT 5 mainstream and LoFlo CAPNOSTAT 5 sidestream can be integrated with virtually any patient monitoring system and provides technologically advanced measurement of end-tidal carbon dioxide and respiration rate. Respironics looks forward to expanding markets for its sensor technology, including the biopharmaceutical market through its collaboration with Sartorius.
Reinhard Vogt, senior vice president of sales and marketing of the Biotechnology Division at Sartorius said the agreement is an example pointing the way to the future in that it shows how an already established technology in medical applications can be transferred to other market segments. "Particularly in the past two years, Sartorius has built up a broad portfolio of disposable technologies with which we anticipated the market trends and have considerably set ourselves apart from the competition." Philip Nuzzo, vice president of OEM and monitoring, explained the benefits of the agreement for Respironics as follows: "Sartorius offers us the opportunity to enter an additional market for our products which further establishes our CO2 technology as the market leader."
Respironics stated that it will not be changing its financial outlook or guidance based on this announcement.
Through this agreement and others like it, Sartorius will continue expanding its portfolio of disposable technologies for the production of biopharmaceuticals.
A Profile of Sartorius
The Sartorius Group is an internationally leading laboratory and process technology provider covering the segments of biotechnology and mechatronics. In 2005, the technology group earned sales revenue of 484.3 million euros. The Goettingen-based company founded in 1870 currently employs approximately 3600 persons. Its biotechnology segment focuses on filtration and separation products, as well as fermenters and bioreactors. The mechatronics segment manufactures, in particular, equipment and systems that feature weighing, measurement, and automation technology for laboratory and industrial applications, as well as hydrodynamic bearings. Key Sartorius customers are from the pharmaceutical, chemical, and food and beverage industries and from numerous research and educational institutes of the public sector. Sartorius has its own production facilities in Europe, Asia, and America, as well as sales subsidiaries and local commercial agencies in more than 110 countries.
Respironics is a leading developer, manufacturer, and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the company is committed to providing valued solutions to help improve outcomes for patients, clinicians, and health care providers. Respironics markets its products in 131 countries and employs over 4700 associates worldwide. Further information can be found on the company's Web site.